Change in tumor size rather than ΔKi67 was the preferred surrogate marker in a placebo-controlled window study of EGFR, Src, or combined blockade in operable HNSCC by Bauman and colleagues (37). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.